Genetic predictors of human chronic pain conditions  by Zorina-Lichtenwalter, Katerina et al.
Neuroscience 338 (2016) 36–62REVIEW
GENETIC PREDICTORS OF HUMAN CHRONIC PAIN CONDITIONSKATERINA ZORINA-LICHTENWALTER, * C. B. MELOTO
S. KHOURY AND L. DIATCHENKO
The Alan Edwards Centre for Research on Pain,
McGill University, 740 Docteur Penfield, Suite 2300, Montreal,
Quebec H3A 0G1, CanadaAbstract—Chronic pain conditions are multifactorial disor-
ders with a high frequency in the population. Their patho-
physiology is often unclear, and treatment is ineﬃcient.
During the last 20 years, genetic linkage analysis and
association studies have made considerable strides toward
identifying key molecular contributors to the onset and
maintenance of chronic pain. Here, we review the genetic
variants that have been implicated in chronic pain condi-
tions, divided into the following etiologically-grouped
categories: migraine, musculoskeletal pain disorders, neu-
ropathic pain disorders, and visceral pain disorders. In rare
familial monogenic pain conditions several strong-eﬀect
mutations have been identiﬁed. In contrast, the genetic land-
scape of common chronic pain conditions suggests minor
contributions from a large number of single nucleotide poly-
morphisms representing diﬀerent functional pathways. A
comprehensive survey of up-to-date genetic association
results reveals migraine and musculoskeletal pain to be
the most investigated chronic pain disorders, in which
nearly half of identiﬁed genetic variability alters neurotrans-
mission pathways.
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INTRODUCTION
Chronic pain is a persistent maladaptive condition,
estimated to aﬀect up to 30% of the world’s population
(Elzahaf et al., 2012). Given the reported heritability of
16–50% (Hocking et al., 2012; Nielsen et al., 2012), a sub-
stantial proportion of the risk of developing a chronic pain
condition is driven by genetic background. To date the
search for contributing genetic variants has yielded an out-
line of a centralized pain-processing system, spearheaded
by neurotransmitters and their receptors and modulated
by myriad other factors, ranging from inﬂammatory cytoki-
nes to growth factors. Although a gestalt understanding is
important for conceptualizing chronic pain, genetic studies
have shown a cosegregation of distinct pathologies with
their putative causal factors at the gene/protein level.
Therefore, it will be helpful to present an overview of the
current knowledge about genetics of chronic pain sepa-
rated by etiology, known or hypothesized.
Numerous genetic risk factors have been identiﬁed for
musculoskeletal, neuropathic, and visceral conditions, as
well as migraine. Among these, migraine and
musculoskeletal pain disorders have undergone the
most extensive investigation in association studies and/licenses/by/4.0/).
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genetic variants (Fig. 1), although many of them await
replication (Fig. 2). The list of chronic pain genes
(Table 1) is a snapshot of the incredible complexity of
the suspected network of molecular interactions. This
list includes genes from catecholaminergic,
serotonergic, estrogenic, glutamatergic, GABAergic,
purinergic and orexinergic pathways; cytokines; growth
factors; and proteinases.
The purpose of this review is threefold: (1) provide an
overview of the current state of knowledge in human
chronic pain genetics, (2) highlight relevant genetic
studies and their outcomes for each pathology category,
and (3) summarize the genomically-derived mechanisms
of molecular pathophysiology for each category.Genetic variability
The human genome is replete with genetic variants. The
majority are germline mutations, passed from parents to
oﬀspring. Less common de novo mutations are not
inherited from parents and occur in oﬀspring only.
Examples of de novo mutations in sodium channels,
Nav1.7, SCN9A, and Nav1.9, SCN11A, have been
described in post-trauma pain perception, congenital
insensitivity to pain, and primary erythromelalgia (Klein
et al., 2012; Leipold et al., 2013). Somatic mutations
acquired during one’s lifetime are not passed on to oﬀ-
spring. These mutations have been implicated in cancer
but so far have not been associated with chronic pain
conditions.Fig. 1. Chronic pain conditions quantiﬁed by the number of genetic assoc
associations is given, including both positive and negative results. Rare Men
Fig. 2. Chronic pain conditions quantiﬁed by the number of genetic loci. O
disorders reported in at least two studies are included, and rare Mendelian dRare but drastic mutations have been identiﬁed as
causal in several monogenic familial disorders, in which
mutations in a single gene locus result in the onset of the
condition. For example, a frameshift mutation, which
severely compromises the function of the encoded
protein, has been discovered in the TWIK-related spinal
cord potassium channel (TRESK) gene, KCNK18, and is
responsible for familial migraine with aura (Lafrenie`re
et al., 2010). A more common type of causal mutation in
rare familial disorders is a nonsynonymous mutation in
one nucleotide that leads to an amino acid change of sub-
stantial functional eﬀect in the resulting protein. Sodium
channels are the best-known example, extensively studied
for their role in monogenic conditions such as erythrome-
lalgia, caused by mutations in SCN9A (Yang et al., 2004).
Unlike the rare, high-impact mutations described
above, common single nucleotide polymorphisms
(SNPs), found in >1% of the population, comprise the
vast majority of human genetic association studies.
These mutations usually have a very minor phenotypic
eﬀect and often exert their eﬀect in concert with speciﬁc
environmental pressures. Rather than directly causing a
chronic pain disease, these SNPs modulate
susceptibility to it. The minor allele contributes either risk
or protection by increasing (conferring gain-of-function
on) or decreasing (conferring loss-of-function on) the
activity of the resultant protein. Approximately 90% of
SNPs are found in introns or intergenic regions, outside
of the protein-coding segments of the gene, outlining
their regulatory role. SNPs that fall in the exonic, or
protein-coding, region may be either non-synonymous,
resulting in a diﬀerent amino acid, or synonymous, notiation studies. For each condition, the number of published genetic
delian disorder variants from linkage studies are not included.
nly genes with positive association in a given disorder or group of
isorder variants from linkage studies are not included.
Table 1. Genes reported in genetic association studies of chronic pain conditions
Gene Function/Pathway Condition(s) Citation
ACAN Structural protein Low back pain Solovieva et al. (2007)
ACE Other Migraine Paterna et al. (2000), Kowa et al. (2005), Lea et al. (2005), Lin et al. (2005),
Kara et al. (2007), Joshi et al. (2009), Alicakmak et al. (2003), Tronvik et al. (2008),
Schu¨rks et al. (2009), Tietjen et al. (2009)
ADAMTSL4 Protein
degradation
Migraine Gormley et al. (2015)
ADARB2 Neurotransmission Migraine Cox et al. (2012)
ADRA1D Neurotransmission TMD Smith et al. (2011)
ADRA2C Neurotransmission TMD Smith et al. (2011)
ADRB2 Neurotransmission TMD Diatchenko et al. (2006)
Low back pain Skouen et al. (2012)
Fibromyalgia Vargas-Alarco´n et al. (2009)
AJAP1 Other Migraine Anttila et al. (2013), Esserlind et al. (2015), Lin et al. (2015), Gormley et al. (2015)
ANKK1 Other Migraine Ghosh et al. (2013)
APOA1BP Metabolism Migraine Anttila et al. (2013)
APOE Metabolism Fibromyalgia Reeser et al. (2011)
AR Other Visceral Pontari (2013)
ARMS2 Other Migraine Gormley et al. (2015)
ASTN2 Other Migraine Freilinger et al. (2012), Esserlind et al. (2015), Gormley et al. (2015)
ATP1A2 Neurotransmission FHM2 Moskowitz et al. (2004)
ATP5B Other Migraine Anttila et al. (2013)
BDNF Cellular growth Migraine Lemos et al. (2010), Sutherland et al. (2014), Marziniak et al. (2008)
C7orf10 Metabolism Migraine Anttila et al. (2013), Esserlind et al. (2015), Lin et al. (2015), Gormley et al. (2015)
CACNA1A Neurotransmission FHM1 Ophoﬀ et al. (1996)
CAMK4 Other TMD Smith et al. (2011)
CARF Other Migraine Gormley et al. (2015)
CASP9 Apoptosis Low back pain Guo et al. (2011), Mu et al. (2013)
CCM2L Other Migraine Gormley et al. (2015)
CCR2 Immune response Migraine Schu¨rks et al. (2009)
CCT5 Structural protein Fibromyalgia Peters et al. (2013)
CFDP1 Other Migraine Gormley et al. (2015)
CFTR Immune response Visceral Sharer et al. (1998), Cohn et al. (1997), Noone et al. (2001)
CGRP Neurotransmission Migraine Lemos et al. (2010)
CHRM2 Neurotransmission TMD Smith et al. (2011)
COMT Neurotransmission Fibromyalgia Vargas-Alarco´n et al. (2007), Ferna´ndez-de-las Pen˜as et al. (2012), Martı´nez-
Jauand et al. (2013), Barbosa et al. (2012), Cohen et al. (2009), Finan et al. (2011),
Matsuda et al. (2010)
Low back pain Rut et al. (2014), Jacobsen et al. (2012), Omair et al. (2012, 2015)
Postoperative pain Rut et al. (2014)
Migraine Cargnin et al. (2013)
Stress-induced
chronic pain
McLean et al. (2011), Bortsov et al. (2014)
TMD Erdal et al. (2003), Diatchenko et al. (2005), Smith et al. (2011), Michelotti et al.
(2014), Meloto et al. (2015)
CPQ Neurotransmission Migraine I.H.G. Consortium et al. (2010)
CRHBP Neurotransmission Stress-induced
chronic pain
Linnstaedt et al. (2016)
Fibromyalgia Holliday et al. (2010)
CXCL8 Immune response TMD Slade et al. (2011)
Cancer pain Reyes-Gibby et al. (2007)
DAO Neurotransmission Migraine Garcı´a-Martı´n et al. (2015)
DBH Neurotransmission Migraine Lea et al. (2000), Fernandez et al. (2006, 2009), Ghosh et al. (2013)
DOCK4 Other Migraine Gormley et al. (2015)
DRD2 Neurotransmission Migraine Peroutka et al. (1998), Del Zompo et al. (1998), Ghosh et al. (2013)
DRD4 Neurotransmission Migraine Del Zompo et al. (1998), Mochi et al. (2003), de Sousa et al. (2007)
TMD Aneiros-Guerrero et al. (2011)
Fibromyalgia Buskila et al. (2004)
EDNRA Other Migraine Tzourio et al. (2001), Tikka-Kleemola et al. (2009)
ESR1 Other TMD Kang et al. (2007), Ribeiro-Dasilva et al. (2009), Kim et al. (2010), Stemig et al.
(2015)
Migraine Colson et al. (2004), Oterino et al. (2006), Kaunisto et al. (2006), Oterino et al.
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Table 1 (continued)
Gene Function/Pathway Condition(s) Citation
(2008), Corominas et al. (2009), Ghosh et al. (2012), Rodriguez-Acevedo et al.
(2013)
Low back pain Roh et al. (2013)
ESR2 Other Migraine Oterino et al. (2008), Ghosh et al. (2012)
FAM183B Other Fibromyalgia Peters et al. (2013)
FGF6 Immune response Migraine Gormley et al. (2015)
FHL5 Other Migraine Anttila et al. (2013), Esserlind et al. (2015), Lin et al. (2015), Gormley et al. (2015)
FKBP5 Immune response Stress-induced
chronic pain
Bortsov et al. (2013)
FSHR Other Migraine Oterino et al. (2008)
FUT9 Metabolism Migraine Anttila et al. (2013)
GABRB3 Neurotransmission Migraine Russo et al. (2005), Netzer et al. (2008)
Fibromyalgia Oswell et al. (2008), Smith et al. (2012)
GBP1 Immune response Fibromyalgia Smith et al. (2012)
GCH1 Metabolism Fibromyalgia Kim et al. (2013)
Peripheral
neuropathy
Hendry et al. (2013)
Postoperative pain Tegeder et al. (2006), Kim et al. (2010)
GDF5 Cellular growth Low back pain Mu et al. (2013)
TMD Xiao et al. (2015)
GJA1 Other Migraine Gormley et al. (2015)
GPR149 Other Migraine Gormley et al. (2015)
GRIA1 Neurotransmission Migraine Formicola et al. (2010), Maher et al. (2013), Cargnin et al. (2014)
GRIA3 Neurotransmission Migraine Formicola et al. (2010), Maher et al. (2013)
GRK5 Other TMD Smith et al. (2011)
GSTM1 Metabolism TMD Aneiros-Guerrero et al. (2011)
HCRTR1 Other Migraine Rainero et al. (2011)
HEY2 Other Migraine Gormley et al. (2015)
HLA-DRB1 Immune response Migraine Rainero et al. (2005)
HPSE2 Metabolism Migraine Gormley et al. (2015)
HTR2A Neurotransmission TMD Mutlu et al. (2004), Ojima et al. (2007) ,Smith et al. (2011), de Freitas et al. (2013),
Slade et al. (2013)
Fibromyalgia Mergener et al. (2011), Holliday et al. (2010), Gu¨rsoy et al. (2001), Bondy et al.
(1999)
HTR7 Neurotransmission Migraine Cox et al. (2012)
IFRD1 Immune response TMD Smith et al. (2011)
IGSF9B Neurotransmission Migraine Gormley et al. (2015)
IL10 Immune response Postoperative pain Stephens et al. (2014)
TMD Smith et al. (2011)
Visceral Shoskes et al. (2002)
IL10RB Immune response Cancer pain Reyes-Gibby et al. (2013)
IL13 Immune response Cancer pain McCann et al. (2012)
IL18R1 Immune response Low back pain Omair et al. (2013)
IL18RAP Immune response Low back pain Omair et al. (2013)
IL1A Immune response Low back pain Schistad et al. (2014), Omair et al. (2013)
IL1B Immune response Migraine Ylmaz et al. (2010)
Cancer pain Reyes-Gibby et al. (2013)
IL1R1 Immune response Cancer pain McCann et al. (2012)
IL1R2 Immune response Postoperative pain Stephens et al. (2014)
IL1RN Immune response Low back pain Loncˇar et al. (2013)
IL9 Immune response Migraine Schu¨rks et al. (2009)
INSR Metabolism Migraine McCarthy et al. (2001)
ITPK1 Metabolism Migraine Gormley et al. (2015)
JAG1 Metabolism Migraine Gormley et al. (2015)
KCNAB3 Neurotransmission Migraine Lafrenie`re and Rouleau (2012)
KCNG4 Neurotransmission Migraine Lafrenie`re and Rouleau (2012)
KCNK18 Neurotransmission Migraine Lafrenie`re et al. (2010), Lafrenie`re and Rouleau (2011)
KCNS1 Neurotransmission Sensory
neuropathy
Hendry et al. (2013)
Postoperative pain Costigan et al. (2010), Hendry et al. (2013)
LDLR Metabolism Migraine Mochi et al. (2003), Curtain et al. (2004)
LRP1 Neurotransmission Migraine Chasman et al. (2011), Esserlind et al. (2015), Gormley et al. (2015), Ghosh et al.
(2013)
(continued on next page)
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Table 1 (continued)
Gene Function/Pathway Condition(s) Citation
LRRIQ3 Other Migraine Gormley et al. (2015)
LTA Immune response Migraine Trabace et al. (2002), Asuni et al. (2009), Ghosh et al. (2010), Ishii et al. (2012)
MAOA Neurotransmission Fibromyalgia Gu¨rsoy et al. (2008)
TMD Mutlu et al. (2005)
MC2R Neurotransmission Fibromyalgia Holliday et al. (2010)
MED14 Metabolism Migraine Gormley et al. (2015)
MEF2D Apoptosis Migraine Freilinger et al. (2012), Esserlind et al. (2015), Gormley et al. (2015)
MMP1 Protein
degradation
Low back pain Song et al. (2008), Jacobsen et al. (2013)
MMP2 Protein
degradation
Low back pain Dong et al. (2007)
MMP3 Protein
degradation
Low back pain Takahashi et al. (2001)
MMP16 Protein
degradation
Migraine Anttila et al. (2013), Esserlind et al. (2015), Gormley et al. (2015)
MNSOD Other Visceral Arisan et al. (2006)
MPPED2 Other Migraine Gormley et al. (2015)
MRVI1 Other Migraine Gormley et al. (2015)
MTDH Other Migraine I.H.G. Consortium et al. (2010), Freilinger et al. (2012), Gormley et al. (2015)
MTHFD1 Other TMD Aneiros-Guerrero et al. (2011)
MTHFR Metabolism Migraine Kowa et al. (2000), Bassi et al. (2003), Kara et al. (2003), Lea et al. (2004), Lea et al.
(2005), Oterino et al. (2005), Bottini et al. (2006), Kaunisto et al. (2006), Scher et al.
(2006), Todt et al. (2006), Pezzini et al. (2007), Ferro et al. (2008), Schu¨rks et al.
(2008), Joshi et al. (2009), Schu¨rks et al. (2009), Tietjen et al. (2009), Liu et al.
(2010), An et al. (2013), Azimova et al. (2013)
MTRR Other TMD Aneiros-Guerrero et al. (2011)
MYT1L Other Fibromyalgia Docampo et al. (2014)
NFKBIA Immune response Cancer pain Reyes-Gibby et al. (2009)
NGFR Cellular growth Migraine Ligthart et al. (2011)
NOS3 Neurotransmission Migraine Borroni et al. (2006), Schu¨rks et al. (2009)
Cancer pain Reyes-Gibby et al. (2013)
NOTCH3 Other Migraine Iso et al. (2003), Alva and Iruela-Arispe (2004)
NOTCH4 Other Migraine Rubino et al. (2013), Gormley et al. (2015)
NR3C1 Immune response TMD Smith et al. (2011)
NRP1 Apoptosis Migraine Gormley et al. (2015)
NRXN3 Neurotransmission Fibromyalgia Docampo et al. (2014)
NTRK1 Other Congenital
insensitivity to pain
Shatzky et al. (2000), Miura et al. (2000), Indo (2001), Indo et al. (2001), Bodzioch
et al. (2001), Bonkowsky et al. (2003), Huehne et al. (2008), Li et al. (2012), Gao
et al. (2013), Liu et al. (2014), Yis et al. (2015), Tang et al. (2014), Wang et al. (2015)
OPRM1 Neurotransmission Stress-induced
chronic pain
Ballina et al. (2013), Linnstaedt et al. (2015)
Low back pain Hasvik et al. (2014), Omair et al. (2015)
Postoperative pain Kolesnikov et al. (2013), Olsen et al. (2012)
Diabethic
neuropathic pain
Cheng et al. (2010)
P2RX7 Neurotransmission Postoperative pain Sorge et al. (2012)
Diabethic
neuropathic pain
Ursu et al. (2014)
PGK1 Metabolism Visceral Riley and Krieger (2002)
PGR Other Migraine Colson et al. (2005)
PHACTR1 Metabolism Migraine Freilinger et al. (2012), Esserlind et al. (2015), Gormley et al. (2015)
PLCE1 Other Migraine Gormley et al. (2015)
POMC Neurotransmission Fibromyalgia Holliday et al. (2010)
PRDM16 Other Migraine Chasman et al. (2011), An et al. (2013), Fan et al. (2014), Esserlind et al. (2015),
Gormley et al. (2015), Ghosh et al. (2013)
PRRT2 Other FHM Riant et al. (2012), Dale et al. (2012)
PRSS1 Protein
degradation
Visceral Whitcomb et al. (1996), Gorry et al. (1997), Noone et al. (2001), Simon et al. (2002),
Le Marechal et al. (2004), Le Mare´chal et al. (2006)
PTGS2 Immune response Migraine Dasdemir et al. (2013), Mozaﬀari et al. (2015)
Cancer pain Reyes-Gibby et al. (2009), Reyes-Gibby et al. (2013)
RAMP1 Other Migraine Sutherland et al. (2013), Cargnin et al. (2015)
REST Other Migraine Gormley et al. (2015)
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Gene Function/Pathway Condition(s) Citation
RNF213 Other Migraine Gormley et al. (2015)
RUNX2 Other TMD Xiao et al. (2015)
SCN1A Neurotransmission FHM3 Dichgans et al. (2005), Persico et al. (2015)
SCN9A Neurotransmission Erythromelalgia Yang et al. (2004), Cummins et al. (2004), Dib-Hajj et al. (2005), Drenth et al.
(2005), Li et al. (2005), Michiels et al. (2005), Han et al. (2006), Zhang et al. (2006),
Lee et al. (2007), Drenth et al. (2008), Lin et al. (2008), Samuels et al. (2008),
Estacion et al. (2009), Han et al. (2009)
Paroxysmal
estreme pain
disorder
Fertleman et al. (2006), Dib-Hajj et al. (2008), Estacion et al. (2008)
Congenital
insensitivity to pain
Cox et al. (2006, 2010), Kurban et al. (2010), Klein et al. (2012), Peddareddygari
et al. (2014), Mansouri et al. (2014), Shorer et al. (2014)
Peripheral
neuropathy
Dabby et al. (2011), Faber et al. (2012a), Han et al. (2012)
Fibromyalgia Vargas-Alarcon et al. (2012)
Visceral Reeder et al. (2013)
SCN10A Neurotransmission Peripheral
neuropathy
Faber et al. (2012b), Huang et al. (2013), Dabby et al. (2016)
SCN11A Neurotransmission Congenital
insensitivity to pain
Leipold et al. (2013), Phatarakyijnirund et al. (2015)
Peripheral
neuropathy
Huang et al. (2014), Han et al. (2015)
SERPINA6 Immune response Fibromyalgia Holliday et al. (2010)
SHMT1 Metabolism TMD Aneiros-Guerrero et al. (2011)
SLC24A3 Neurotransmission Migraine Gormley et al. (2015)
SLC6A4 Neurotransmission Fibromyalgia Oﬀenbaecher et al. (1999)
Migraine Ylmaz et al. (2001), Kotani et al. (2002), Gonda et al. (2007), Todt et al. (2006)
TMD Herken et al. (2001), Ojima et al. (2007)
Trigeminal
neuralgia
Cui et al. (2014)
SMAD3 Other TMD Xiao et al. (2015)
SPINK1 Protein
degradation
Visceral Witt et al. (2000), Pfuetzer et al. (2001), Kira´ly et al. (2007)
STAT6 Other Migraine Anttila et al. (2013)
TAAR1 Neurotransmission Fibromyalgia Smith et al. (2012)
TBC1D7 Cellular growth Migraine Anttila et al. (2013)
TGFB1 Cellular growth TMD Slade et al. (2011)
Migraine Schu¨rks et al. (2009)
TGFBR2 Cellular growth Migraine Freilinger et al. (2012), Esserlind et al. (2015), Gormley et al. (2015)
TNF Immune response Migraine Mazaheri et al. (2006), Ghosh et al. (2010), Ylmaz et al. (2010), Ates et al. (2011),
Gu et al. (2012), Schu¨rks et al. (2009), Trabace et al. (2002), Asuni et al. (2009)
Cancer pain Reyes-Gibby et al. (2009)
TNFRSF1B Immune response Migraine Dong et al. (2012)
Cancer pain Reyes-Gibby et al. (2013)
TRPA1 Neurotransmission Sensory
neuropathy
Binder et al. (2012)
TRPM8 Neurotransmission Migraine Chasman et al. (2011), Freilinger et al. (2012), Esserlind et al. (2015), Gormley et al.
(2015)
TRPV1 Neurotransmission Migraine Carren˜o et al. (2012)
sensory
neuropathy
Binder et al. (2012)
TRPV3 Neurotransmission Migraine Carren˜o et al. (2012)
TSPAN2 Other Migraine Anttila et al. (2013), Esserlind et al. (2015), Gormley et al. (2015)
WSCD1 Metabolism Migraine Gormley et al. (2015)
YAP1 Apoptosis Migraine Gormley et al. (2015)
ZCCHC14 Other Migraine Gormley et al. (2015)
Abbreviations: FHM, familial hemiplegic migraine; TMD, temporomandibular disorder.
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synonymous or non-synonymous, most common SNPs
are silent and have no clearly observable or discernible
phenotypic eﬀect.Several databases, such as NCBI dbSNP (http://www.
ncbi.nlm.nih.gov/snp), the 1000genomes project (http://
www.1000genomes.org), and Ensembl (http://www.
ensembl.org), inventory known SNPs and annotate
42 K. Zorina-Lichtenwalter et al. / Neuroscience 338 (2016) 36–62them with genomic location, population distribution,
expression, and functional eﬀect, adding disease
association information where available. The recently
launched Human Pain Genetics Database
(http://diatchenko.lab.mcgill.ca/hpgdb) is a manually-
curated repository for SNPs in human genes reported to
be associated with pain conditions or intermediate
phenotypes.
Human genetic studies
With few exceptions, chronic pain does not follow the
Mendelian transmission model. Rather, chronic pain
pathologies are typically aggregates of endophenotypes,
each of which may be governed by Mendelian law. A
construct developed for the study of complex diseases
in neuropsychiatry, endophenotypes must (1) be
heritable, (2) be associated with the disease of interest,
(3) be manifest in subjects independently of active
pathology, and (4) cosegregate with disease in pedigree
studies (Gottesman and Gould, 2003). In this case,
endophenotypes are symptoms of chronic pain condi-
tions. They include sleep disturbance, fatigue, depres-
sion, cognitive decline, and hypersensitivity to external
stimuli.
The two predominant ways geneticists screen human
subjects for mutations associated with chronic pain are
linkage analysis and association studies. For linkage
analysis available family members are phenotyped and
genotyped to see which genetic locus or loci will
segregate with the disease. This method has been used
to identify a rare mutation in KCNK18, encoding the
above-mentioned potassium channel TRESK (Lafrenie`re
et al., 2010). Naturally, this type of study depends on
access to several generations of a pedigree. Linkage
analysis is eﬃcient for the identiﬁcation of rare familial
mutations.
Association studies, used to identify common
functional SNPs, require large populations of unrelated
subjects with the pathology of interest to be matched
against a population of healthy controls. Their DNA is
genotyped using either a targeted selection or a
genome-wide high-density panel of SNPs. Given the
high number of subjects needed in order to provide
suﬃcient statistical power, genome-wide association
studies (GWAS) are usually done through collaboration
of many research institutions. Results from association
studies can be further combined in meta-analysis to get
reliable association metrics for tested SNPs. The
implementation and maturation of large consortia during
the past decade have led to valuable online resources,
such as NHGRI (https://www.genome.gov) and NCBI
dbGaP (http://ncbi.nlm.nih.gov/gap), which oﬀer
comprehensive catalogs of GWAS results. However, to
date the number of GWAS on chronic pain conditions is
very limited. Study design is complicated by lack of
standardized chronic pain phenotype deﬁnitions,
heterogeneity in clinical reporting, and comorbidities
(Holliday and McBeth, 2011). Migraine is the exception:
four GWAS (I.H.G. Consortium et al., 2010; Chasman
et al., 2011; Freilinger et al., 2012; Cox et al., 2012) and
three GWAS meta-analyses (Ligthart et al., 2011; Anttilaet al., 2013; Gormley et al., 2015) have been reported
for this condition. A ﬁbromyalgia GWAS (Docampo
et al., 2014) and a GWAS meta-analysis for chronic wide-
spread pain (CWP) (Peters et al., 2013) have been
recently published as well.Animal models
While human studies are limited by accessibility to
subjects with the genotypes of interest, in animal
models, target genotypes can be engineered and
screened. The mouse is the most common model
organism in pain genetics. Back-crossing and selective
inbreeding are done to isolate a particular locus on a
wild-type background. A gene of interest is knocked out,
knocked down, or a human clone is knocked in to
observe its eﬀect on a particular pathology. Transgenic
mouse models have been reviewed in Mogil and Grisel
(1998). Certainly, phenotype characterization is more dif-
ﬁcult given non-verbal subjects, and genomic and physio-
logical diﬀerences between the two species necessarily
result in phenotypic discrepancies. Mouse model devel-
opers must demonstrate that their models are suﬃciently
similar to the human condition under study to be informa-
tive. Despite these diﬃculties, a number of models (Mogil,
2009) have been very instrumental in either identifying
genes involved in chronic pain conditions or conﬁrming
their relevance after identiﬁcation in a human study. Neu-
ropathic pain models include spared nerve injury (SNI),
chronic constriction injury (CCI), diabetic, and cancer pain
(Wang and Wang, 2003). Inﬂammatory pain models use
injections of immune system stimulants, such as Freund’s
adjuvant and carrageenan, as well as nociceptor sensi-
tizer brandykinin, and pro-inﬂammatory cytokines. Orofa-
cial and visceral chronic pain states are modeled using
site-speciﬁc injections of inﬂammatory agents
(Krzyzanowska and Avendan˜o, 2012). Several migraine
mouse models have been likewise described. While ear-
lier studies focused on brain structural-anatomical singu-
larities and electrophysiology experiments in transgenic
animals with alterations in causal genes (van den
Maagdenberg et al., 2004), more recent models have
endeavored to ﬁnd a behavioral proxy for migraine symp-
toms in mice (Langford et al., 2010).METHODS
The list of studies reporting genes associated with chronic
pain disorders was drawn from the Human Pain Genetics
Database (http://diatchenko.lab.mcgill.ca/hpgdb). This list
was supplemented with a literature search in Google
Scholar for studies reporting suggested association or
negative results. For each disorder, the search terms
included the name of the disorder and the gene as well
as one of the following terms: ‘‘genetic association”,
‘‘variant”, or ‘‘polymorphism”. Studies of disorders in
which pain is not the primary symptom, such as
diabetes and cancer, were only included if the ﬁnding
speciﬁcally stated association with pain. Publications
were screened by title and abstract; in cases where
these presented insuﬃcient information, the text of the
publication and relevant tables was read. Reviews and
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cohort were excluded.
With the exception of several large populations
studies, which are speciﬁed below, the majority of the
studies conducted to date have been done on small
population samples (fewer than 1000 individuals).
Additionally, excepting four migraine GWAS (I.H.G.
Consortium et al., 2010; Chasman et al., 2011; Cox
et al., 2012; Freilinger et al., 2012), three migraine GWAS
meta-analyses (Ligthart et al., 2011; Anttila et al., 2013;
Gormley et al., 2015), one ﬁbromyalgia GWAS
(Docampo et al., 2014), and one CWP GWAS meta-
analysis (Peters et al., 2013), all studies were
candidate-gene studies or gene panel studies. While the
number of GWAS and sequencing studies continues to
rise, candidate gene association studies have played an
important role in our understanding of the genotypic struc-
ture of human pain phenotypes. Although these
hypothesis-driven studies risk oversight of untested cau-
sal genetic variants and augment the chances of false
positive associations (Rivadeneira et al., 2009;
Rajasekaran et al., 2013), when replicated in multiple
cohorts, they point to functional variants and the direction
of their eﬀects.RESULTS
Migraine
Migraine, a complex and debilitating pain disorder, is
estimated to aﬀect up to 25% of women and 8% of men
(Launer et al., 1999). Similar to musculoskeletal condi-
tions, up to 50% of migraine etiology has been attributed
to genetic factors (Honkasalo et al., 1995). Numerous
migraine genetics reviews have been published in the last
decade (de Vries et al., 2009; Schu¨rks, 2012; Rudkjobing
et al., 2012; Kurth, 2013; Persico et al., 2015), and the
number of genes with reported statistically signiﬁcant
association exceeds that of all other chronic pain condi-
tions (Fig. 1). Notably, some of these genes were identi-
ﬁed in GWAS. Partly as a testament to its clearly
deﬁned diagnostic criteria – lacking for most other
pathologies discussed here – migraine is one of the few
chronic pain conditions to have undergone GWAS, of
which there are four to date (I.H.G. Consortium et al.,
2010; Chasman et al., 2011; Cox et al., 2012; Freilinger
et al., 2012). The last of these was done in a
genetically-isolated Norfolk Island population (Cox et al.,
2012). In addition, there have been three meta-analyses
(Ligthart et al., 2011; Anttila et al., 2013; Gormley et al.,
2015), the last of which is the most comprehensive
reported migraine genetic study of individuals with Euro-
pean ancestry, having analyzed a total of 375,000 individ-
uals and having identiﬁed 38 loci of susceptibility,
replicating 10 previously published associations.
The paradigm of migraine causality continues to shift
between vascular dysregulation and neuronal
hyperexcitability, as compelling evidence continues to
accumulate for both theories. Genetic studies have
contributed signiﬁcantly to the current understanding of
its molecular pathophysiology.Familial hemiplegic migraine (FHM). Rare mutations
in three genes have been reported as causal in FHM:
CACNA1A in FHM1 (Ophoﬀ et al., 1996); ATP1A2 in
FHM2 (Moskowitz et al., 2004); and SCN1A in FHM3
(Dichgans et al., 2005). The CACNA1A-encoded alpha-
1 subunit of a P/Q voltage-gated calcium channel, also
reported to be involved in cortical spreading depression,
has gain-of-function mutations that lead to channel
responsiveness at lower voltages and contribute to a
state of neuronal hyperexcitability. ATP1A1-encoded
alpha-1 subunit of the sodium–potassium ATPase pump
aﬀects its ability to pump sodium ions against the concen-
tration gradient, necessary for glutamate and calcium ﬂow
(Moskowitz et al., 2004). SCN1A encodes the alpha-1
subunit of a voltage-gated neuronal sodium channel,
and its minor allele hastens the channel’s recovery from
fast inactivation, increasing cortical neuron ﬁring fre-
quency (Dichgans et al., 2005). Proline- rich transmem-
brane protein 2, PRRT2, is a recent addition to the list.
Mutations in this gene have also been implicated in hemi-
plegic migraine (Dale et al., 2012; Riant et al., 2012). Not
an ion channel like the other three FHM variants, PRRT2
may be involved in neuronal exocytosis and release of
neurotransmitters by aﬀecting localization and kinetics of
channels such as CACNA1A (Riant et al., 2012). FHM1-
3 causal variants and PRRT2, discovered through pedi-
gree linkage mapping, are responsible for rare migraine
disorders.Migraine: vascular origins. Genetic association
studies have also identiﬁed variants with higher
frequency and lower eﬀect, thought to be involved in the
much more prevalent nonhemiplegic migraine. Unlike
the FHM disorders, the hypothesized causality of the
more common migraine may or may not be limited to
hyper-neuroexcitation. Evidence continues to
accumulate for the involvement of the originally-
suspected vascular system dysregulation. According to
the vascular hypothesis, cogently summarized in Tietjen
(2009), a combination of inadequate response to oxida-
tive stress, lower levels of vasodilators, and increased
numbers of vasoconstrictors brings about endothelial dys-
function, which may lead to an elevated level of proinﬂam-
matory cytokines circulating in the extracellular matrix.
Genetic variants supporting vascular dysregulation in
migraine include EDNRA, encoding endothelin type A
receptor (Tzourio et al., 2001; Tikka-Kleemola et al.,
2009); MTHFR, encoding methylenetetrahydrofolate
reductase (Kowa et al., 2000; Bassi et al., 2003; Kara
et al., 2003; Lea et al., 2004; Lea et al., 2005; Oterino
et al., 2005; Bottini et al., 2006; Scher et al., 2006;
Pezzini et al., 2007; Schu¨rks et al., 2008; Schu¨rks et al.,
2009; Tietjen et al., 2009; An et al., 2013; Azimova
et al., 2013; Liu et al., 2010); NOS3, encoding endothelial
nitric oxide synthase (Borroni et al., 2006; Schu¨rks et al.,
2009); ACE, encoding angiotensin-1 converting enzyme
(Paterna et al., 2000; Kowa et al., 2005; Lea et al.,
2005; Lin et al., 2005; Kara et al., 2007; Joshi et al.,
2009); NOTCH3, encoding a receptor involved in vascular
development and integrity (Iso et al., 2003; Alva and
Iruela-Arispe, 2004); TGFB1, encoding beta-2 transform-
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encoding beta-2 transforming growth factor receptor
(Freilinger et al., 2012; Esserlind et al., 2015; Gormley
et al., 2015) (which has not shown an association in a
North Indian population (Ghosh et al., 2013)). As further
evidence for the involvement of the vascular system in
migraine pathophysiology, Winsvold et al. have recently
reported a large overlap between associated loci in a
multi-study migraine GWAS meta-analysis and coronary
artery disease GWAS (Winsvold et al., 2015). Speciﬁ-
cally, migraine without aura and coronary artery disease
share signiﬁcantly associated SNPs but in opposite
directions.
Migraine: inflammatory markers. A vast number of
genetic association studies have implicated a modiﬁed
inﬂammatory state in migraine directly by showing a
correlation between alleles of cytokines TNF-alpha, TNF
(Mazaheri et al., 2006; Schu¨rks et al., 2009; Ghosh
et al., 2010; Ylmaz et al., 2010; Ates et al., 2011; Gu
et al., 2012) (not replicated in Trabace et al. (2002) and
Asuni et al. (2009)), and TNF-beta, LTA, with migraine
(Trabace et al., 2002; Asuni et al., 2009; Ghosh et al.,
2010; Ishii et al., 2012). A tumor necrosis factor receptor
superfamily member, TNFRSF1B, has also been impli-
cated as a risk factor in migraine susceptibility in a Han
Chinese population (Dong et al., 2012); as have inter-
leukin 1-beta, IL1B (Ylmaz et al., 2010); interleukin 9,
IL9; chemokine receptor, CCR2 (Schu¨rks et al., 2009);
and prostaglandin endoperoxide synthase 2, PTGS2
(Dasdemir et al., 2013; Mozaﬀari et al., 2015).
Migraine: neuronal origins. Current evidence is
arguably strongest for susceptibility to migraine lying at
the intersection of increased ascending nociceptive
signaling and reduced descending inhibition (Akerman
et al., 2011). Implicated signaling systems involve gluta-
matergic, serotonergic, dopaminergic, GABAergic, orex-
inergic and purinergic transmission.
In the glutamatergic system, whose involvement in
migraine has been recently reviewed in Gasparini and
Griﬃths (2013), AMPA receptors, GRIA1 (Formicola
et al., 2010) (not found to be associated in Cargnin
et al. (2014) and Maher et al. (2013)) and GRIA3
(Formicola et al., 2010; Maher et al., 2013); glutamate
receptor GRM7 (Cox et al., 2012); as well as glutamate-
regulating metahedrin, MTDH (I.H.G. Consortium et al.,
2010; Freilinger et al., 2012; Gormley et al., 2015);
lipoprotein receptor, LRP1 (Chasman et al., 2011;
Ghosh et al., 2013; Esserlind et al., 2015; Gormley
et al., 2015); myocyte enhancer factor, MEF2D
(Freilinger et al., 2012; Esserlind et al., 2015; Gormley
et al., 2015); and a variant near plasma glutamate car-
boxypeptidase, CPQ (I.H.G. Consortium et al., 2010)
have been reported as associated with migraine. Except
for the two AMPA receptors, all these genes were top hits
in migraine GWAS, replicated in a later GWAS or in sub-
sequent targeted SNP genotyping projects (Freilinger
et al., 2012; Esserlind et al., 2015).
The role of serotonergic transmission in migraine has
been comprehensively reviewed in Hamel (2007). Sero-tonin receptor, HTR7, has been shown to be associated
in a Norfolk Island population GWAS (Cox et al., 2012).
Likewise, an association with migraine has been reported
for serotonin transporter, SLC6A4, in a Turkish population
(Ylmaz et al., 2001) and a Japanese population (Kotani
et al., 2002). Furthermore, Gonda et al. have reported
an association between this locus and migraine comorbid
with anxiety (Gonda et al., 2007). However, SLC6A4 has
not been found to be signiﬁcantly associated in a German
cohort (Todt et al., 2006), which may indicate that the
eﬀect is race-speciﬁc.
Dopaminergic involvement, recently reviewed in
Barbanti et al. (2013), is of particular interest given its
reported association not only with migraine but also with
anxiety and depression (both well-established comorbidi-
ties with migraine (Pesa and Lage, 2004; Ligthart et al.,
2013)). Peroutka et al. and Del Zompo et al. have dis-
cussed dopaminergic pathway-mediated changes in cere-
bral blood ﬂow (observed during cortical spreading
depression) and somatosensory hyperactivity (Del
Zompo et al., 1998; Peroutka et al., 1998), which would
explain prodromal symptoms such as moodiness, drowsi-
ness, and nausea (Fanciullacci et al., 1999; D’Andrea
et al., 2006). Dopamine beta-hydroxylase, DBH (Lea
et al., 2000; Fernandez et al., 2006, 2009; Ghosh et al.,
2013); dopamine D2 receptor, DRD2 (Del Zompo et al.,
1998; Peroutka et al., 1998; Ghosh et al., 2013); and
dopamine D4 receptor, DRD4 (Mochi et al., 2003; de
Sousa et al., 2007) (which has been reported not associ-
ated in Del Zompo et al. (1998)) have all been implicated
in migraine and some of the associated non-headache
symptoms. DRD2 has also been reported to be associ-
ated with aura, anxiety and depression (Del Zompo
et al., 1998; Peroutka et al., 1998), as well as aortic steno-
sis, another vascular disorder (Guauque-Olarte et al.,
2015). Cargnin et al. have reported on the role of
dopamine-degrading catechol-O-methyl transferase
COMT in the response to triptans for migraine (Cargnin
et al., 2013).
GABAergic involvement has been demonstrated
through association with a GABA-A receptor, GABRB3
(Russo et al., 2005; Netzer et al., 2008) (not replicated
in Oswell et al. (2008)). Additionally, a sodium channel,
SCN1A, hypoactive variant has been shown to suppress
the activity of GABAergic inhibitory interneurons
(Persico et al., 2015).
The orexinergic system, whose suspected role in
migraine has been recently reviewed in Hoﬀmann et al.
(2015), is implicated through an association between
migraine and hypocretin receptor 1, HCRTR1 (Rainero
et al., 2011). Hypocretin is a neuropeptide that regulates
arousal, wakefulness, and appetite.
The purinergic system may be involved as well, as
evidenced by association for adenosine deaminase,
ADARB2 (Cox et al., 2012) and mitochondrial ATP syn-
thase, ATP5B (Anttila et al., 2013), both GWAS results,
and purinergic receptor 7, P2RX7, which has so far been
linked to migraine in a mouse model (Go¨lo¨ncse´r and
Sperla´gh, 2014).
Further evidence for dysregulated neuronal
excitability comes from associations between migraine
Fig. 3. Genetic loci associated with migraine, quantiﬁed by the number of genetic association studies. Only genes with association reported in at
least two studies are included in the analysis, and only genes with association reported in at least four studies are listed individually. Genes with
fewer reported associations are grouped under ‘‘Other.” Abbreviations: MTHFR, methelynetetrahydrofolate reductase; ACE, angiotensin I
converting enzyme; PRDM16, PR domain-containing 16; TNF, tumor necrosis factor; ESR1, estrogen receptor 1; AJAP1, adherens junctions-
associated protein 1; C7orf10, succinyl-CoA:glutarate-CoA transferase; DBH, dopamine beta-hydroxylase; FHL5, four-and-a-half LIM domains 5;
LRP1, low density lipoprotein receptor related protein 1; LTA, lymphotoxin alpha; MMP16, matrix metalloproteinase 16; TRPM8, transient receptor
potential cation channel, subfamily M, member 8 (menthol and cold receptor). Rare Mendelian disorder variants from linkage studies are not
included.
Fig. 4. Functional pathways of genetic loci associated with migraine quantiﬁed by the number of loci. Only genes with at least one replicated
association are included. Rare Mendelian disorder variants from linkage studies are not included. For genes reported to be involved in multiple
pathways, the pathway of the translated gene’s most direct involvement was chosen.
Fig. 5. Genetic loci associated with musculoskeletal pain disorders, quantiﬁed by the number of genetic association studies. Only genes reported to
be associated with a musculoskeletal pain disorder in at least two studies are included, and only genes with association reported in at least three
studies are listed individually. Genes with fewer reported associations are grouped under ‘‘Other.” Abbreviations: COMT, catechol-O-methyl
transferase; HTR2A, 5-hydroxytryptamine (serotonin) receptor 2A; ESR1, estrogen receptor 1; ADRB2, beta-2 adrenergic receptor; GCH1, GTP
cyclohydrolase; OPRM1, mu-1 opioid receptor; SLC6A4, solute carrier family 6 (serotonin transporter).
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cation exchanger, SLC24A3 (Gormley et al., 2015); phos-
phatase and actin regulator, PHACTR1; astrotactin,ASTN2 (Freilinger et al., 2012; Esserlind et al., 2015;
Gormley et al., 2015); and transcription enhancer, FHL5
(Anttila et al., 2013; Esserlind et al., 2015; Gormley
Fig. 6. Functional pathways of genetic loci associated with musculoskeletal disorders quantiﬁed by the number of loci. Only genes with at least one
replicated association are included. For genes reported to be involved in multiple pathways, the pathway of the translated gene’s most direct
involvement was chosen.
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have announced key rare variants in the ﬁrst gene to be
implicated through a linkage mapping pedigree study in
nonhemiplegic migraine: KCNK18, encoding the potas-
sium channel TRESK (Lafrenie`re et al., 2010; Lafrenie`re
and Rouleau, 2011). Considering the likelihood of neu-
roexcitability as the main culprit, the same research group
has targeted a panel of ion channels, transporters,
exchangers and accessory subunits and found two more
potassium channels, KCNG4 and KCNAB3, to be associ-
ated with migraine (Lafrenie`re and Rouleau, 2012).
Likewise, Cox et al. (2011) have reported a calcium-
activated potassium ion channel, KCNN3, variant to be
protective against migraine. Lemos et al. have shown a
signiﬁcant interaction between brain-derived neurotrophic
factor, BDNF (also reported to be associated in
Sutherland et al. (2014) but not in Marziniak et al.
(2008)), and calcitonin gene-related peptide, CGRP, with
migraine (Lemos et al., 2010). Histamine-degrading
enzyme, diamine decarboxylase, DAO, has likewise been
reported associated in a Caucasian Spanish population
(Garcı´a-Martı´n et al., 2015). A mild association has been
reported for a variant in RAMP1 – a CGRP receptor sub-
unit – with migraine in Sutherland et al. (2013) and with
migraine changing into medication-overuse headache
(Cargnin et al., 2015) (although another group has
reported no signiﬁcant association with medication over-
use headache in migraineurs (Ishii et al., 2015).
Other genes that have been identiﬁed in genetic
association studies include estrogen receptors, ESR1
(Colson et al., 2004; Oterino et al., 2006, 2008; Ghosh
et al., 2012; Rodriguez-Acevedo et al., 2013) (not repli-
cated in Corominas et al. (2009)) and ESR2 (Oterino
et al., 2008) (not replicated in Ghosh et al. (2012)); follicle
stimulating hormone receptors FSHR (Oterino et al.,
2008); progesterone receptor, PGR (Colson et al., 2005)
(not replicated in Corominas et al. (2009)); low-density
lipoprotein, LDLR (Mochi et al., 2003) (not replicated in
Curtain et al. (2004)); and human leukocyte antigen,
HLA-DRB1 (Rainero et al., 2005); insulin receptor, INSR
(McCarthy et al., 2001); and ankyrin repeat and kinase
domain containing 1, ANKK1 (Ghosh et al., 2013).
Another is PRDM16, whose minor allele was one of three
signiﬁcantly associated risk variants coming from the sec-
ond migraine GWAS (the other two being TRPM8, dis-
cussed below, and LRP1, discussed above) (Chasman
et al., 2011). As a transcription factor involved in brownfat development, PRDM16 is a dubious suspect in terms
of migraine pathology. This association has, however,
been replicated in two Chinese population studies (An
et al., 2013; Fan et al., 2014) and two large-population
European studies (Esserlind et al., 2015; Gormley et al.,
2015). Another replication attempt has reported associa-
tion in the opposite direction (as a protective variant)
(Ghosh et al., 2013), and the same study has also
reported positive replication for LRP1. In addition, Chris-
tensen et al. have reported a role for PRDM16 in modulat-
ing migraineurs’ response to treatment with triptans
(Christensen et al., 2015). Rubino et al. have reported
an association for neurogenic locus notch homolog pro-
tein NOTCH4 with migraine (Rubino et al., 2013), repli-
cated in the largest GWAS meta-analysis to date
(Gormley et al., 2015).
Another high-powered meta-analysis of 23,285
individuals with migraine and 95,425 controls
demonstrated signiﬁcant associations with adherens
junction-associated protein 1, AJAP1; tetraspanin,
TSPAN2; succinyl–CoA:glutarate–CoA transferase,
C7orf10; matrix metalloproteinase 16, MMP16;
apolipoprotein A–I binding protein, APOA1BP;
fucosyltransferase 9, FUT9; interleukin 4-induced
activator of transcription 6, STAT6; and TBC1 domain
family member, TBC1D7 (Anttila et al., 2013). AJAP1,
MMP16 and C7orf10 have been replicated in a Chinese
population (Lin et al., 2015) and two other GWAS
(Esserlind et al., 2015; Gormley et al., 2015), which have
also replicated the association for TSPAN2. Nerve growth
factor receptor-encoding NGFR has also been found
associated in a six-center GWAS meta-analysis in Dutch
and Icelandic populations (Ligthart et al., 2011). There
has likewise been an association reported for a locus in
the mitochondrial DNA with migraine, both with and with-
out aura (Guo et al., 2015).
Migraine has been aptly styled ‘‘a cycle of painful
signaling and interpretation of nonpainful stimuli as
painful” (Karsan and Goadsby, 2015). In line with the lat-
ter part of this statement, the reported contribution of pri-
mary aﬀerent nociceptor-expressed transient receptor
potential receptors adds a central sensitization compo-
nent to the pathophysiological agglomerate that leads to
the migraine disorder. Light, heat, and mechanical sen-
sors – vanilloid receptors, TRPV1 and TRPV3 (Carren˜o
et al., 2012), – and a cold temperature and menthol
receptor, TRPM8, found to be associated with migraine
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et al., 2012; Esserlind et al., 2015; Gormley et al.,
2015), suggest that migraineurs’ pain is engendered by
nociceptive response to physiologically-innocuous stimuli.
Migraine genetics: summary. Among chronic pain
conditions, genetic studies of migraine are the most
abundant (Fig. 2) and have output at least 30 diﬀerent
genes with replicated association (Fig. 3). The most
highly cited gene is MTHFR, (Fig. 3) encoding a
metabolic mediator that participates in the conversion of
homocysteine to methionine. Given that homocysteine
derivatives can activate NMDA receptors, there is a
connection between MTHFR and glutamatergic
signaling. Neurotransmission is furthermore the best
represented pathway in migraine (Fig. 4). Nevertheless,
migraine etiology, which continues to mystify basic and
clinical researchers alike, is well represented by the
proportional distribution of the other functional pathways
in Fig. 4. The large variety of genetic mediators of
migraine is consistent with the observed heterogeneous
nature of this disorder.
Musculoskeletal conditions
Musculoskeletal pain conditions include
temporomandibular disorder (TMD), low back pain,
ﬁbromyalgia, and CWP. These disorders, whose
heritability estimate is up to 50%, have been recently
characterized in terms of their phenotypic and genetic
markers in Diatchenko et al. (2013). Additionally, a num-
ber of publications have reported a possible role for
genetic variants in susceptibility to chronic musculoskele-
tal pain following a psychologically-traumatizing event, or
stress-induced chronic pain.
TMD. TMD is the most frequently occurring class of
orofacial pain conditions, with an estimated prevalence
between 3% and 12% worldwide (Lavigne and Sessle,
2015). This heterogeneous set of conditions exhibits great
interindividual variability in manifestation and response to
treatment as well as high comorbidity with other pain con-
ditions. Their etiology, however, is still unclear. There is
lack of understanding of orofacial pain mechanisms and
their modifying factors (Sessle, 2014), which leads to lack
of accurate diagnoses and eﬀective treatment. Given a
reported heritability of 27% (Plesh et al., 2011), TMD
genetics, reviewed recently in Visscher and Lobbezoo
(2015), has emerged as a powerful tool to aid in research
and help clinicians deepen their comprehension of causal
factors with the ultimate goal of providing eﬀective and
suitable treatment to patients.
While most studies to date have been done on small
populations, the OPPERA (Orofacial Pain: Prospective
Evaluation and Risk Assessment) project represents a
multi-center, high-powered eﬀort to identify genetic
markers contributing to TMD (Dworkin, 2011). Although
the OPPERA GWAS is underway (Munzenmaier et al.,
2014), to date only targeted genotyping studies have
been published by this group on a subset of this cohort
and by others. These studies have nevertheless identiﬁed
a number of genetic variants that implicate catecholamin-ergic, estrogenic, and serotonergic systems. Evidence
also exists for the involvement of cytokines and other
molecules in causal pain pathways, but their role is still
poorly understood.
Involvement of the catecholaminergic system in TMD
is exempliﬁed by COMT, the most studied and cited gene
in human pain genetics (Mogil, 2012). This gene encodes
the catechol-O-methyltransferase enzyme, which regu-
lates the levels of catechol neurotransmitters. Its hypoac-
tivity leads to a higher level of epinephrine, which
potentiates beta adrenergic receptor-mediated pain sig-
naling (Nackley et al., 2007). COMT is a highly polymor-
phic gene with multiple functional SNPs. The most
studied SNP is the non-synonymous val158met variation
implicated in multiple pain conditions, mood disorders and
cognitive function in a number of studies (Goldberg et al.,
2003; Zubieta et al., 2003; Tunbridge et al., 2006; McLean
et al., 2011; Smith et al., 2011; Michelotti et al., 2014).
Furthermore, three major functional haplotypes in the
coding region of the gene have shown strong association
with response to noxious stimuli and risk of myogenous
TMD in humans (Diatchenko et al., 2005). A recently iden-
tiﬁed regulatory SNP in the 30-untranslated region of
COMT has led to the discovery of a functional alternate
isoform of the COMT enzyme, shown in vitro to have pre-
ferred enzymatic activity toward dopamine, which may
contribute to pain by lowering the level of dopamine rather
than increasing the level of epinephrine (Meloto et al.,
2015). On the other hand, variants in COMT have been
reported not to be signiﬁcantly associated with TMD in a
Turkish population (Erdal et al., 2003).
Adrenergic receptor involvement has also been
reported. Both hyperactive and hypoactive variants of
beta adrenergic receptor ADRB2 have been shown as
possible modulators of TMD risk (Diatchenko et al.,
2006). Two alpha adrenergic receptors, ADRA2C and
ADRA1D, have been reported as possibly signiﬁcant
TMD risk modulators (Smith et al., 2011).
Two common genetic variants in the human estrogen
receptor ESR1 have been implicated in painful
temporomandibular joint (TMJ) disk displacement in a
Brazilian female population (Ribeiro-Dasilva et al.,
2009). One of the associations has been replicated in Kor-
ean patients with TMJ osteoarthritis (TMJ-OA) (Kang
et al., 2007), although another Korean cohort with TMD
has shown a trend but no statistically signiﬁcant associa-
tion for the same SNP (Kim et al., 2010). Recently,
another study has shown these variants as associated
with the TMJ degenerative process, possibly via modula-
tion of ESR1 activity in the bone (Stemig et al., 2015).
Given that TMJ is a well-documented target tissue for
estrogen (Abubaker et al., 1993; Yamada et al., 2003;
Galal et al., 2008), it is not surprising to ﬁnd estrogen
receptor genetic variants involved in the pathophysiology
of its disorders.
The serotonergic system has been implicated in TMD
pathophysiology via polymorphisms in serotonin receptor,
HTR2A, (Mutlu et al., 2004; Smith et al., 2011; de Freitas
et al., 2013; Slade et al., 2013) (not replicated in Ojima
et al. (2007)), and serotonin transporter, SLC6A4, which
have shown association in diﬀerent populations (Herken
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insertion/deletion polymorphism within the promoter
region, presenting two allelic forms, long (l) and short
(s). It also has a polymorphic region of a 17bp-variable
number of tandem repeats (VNTR) in its second intron.
Both polymorphic regions have shown association with
TMD: the promoter region in a Japanese population
(Ojima et al., 2007) and VNTR in a Turkish population
(which has not shown an association for the promoter
region) (Herken et al., 2001).
Numerous studies have shown that levels of
proinﬂammatory cytokines are heightened in the TMJ
ﬂuid of TMD patients (Kubota et al., 1998; Alstergren,
2000) and that these levels correlate with greater pain
sensitivity (Ferreira et al., 1988; Salemi et al., 2003;
Sommer and Kress, 2004; Alexander et al., 2005), per-
ceived stress (Maes et al., 1998) and depression
(Raison et al., 2006), all of which are phenotypes associ-
ated with TMD (Maixner et al., 1998; Yap et al., 2002;
Slade et al., 2007; Fillingim et al., 2013). In addition, ele-
vated levels of proinﬂammatory cytokines have been con-
sistently reported in circulating blood of patients with
widespread pain (Wallace et al., 2001; Salemi et al.,
2003). Genetic evidence for the involvement of cytokines
in TMD has been therefore explored and reported (Slade
et al., 2011). While no individual SNPs have shown asso-
ciation with TMD, two SNPs within the interleukin 8 gene,
CXCL8, interacted similarly and signiﬁcantly with a trans-
forming growth factor TGFB1 SNP, producing the great-
est eﬀect on TMD with widespread pain. A variant in
interleukin 10, IL10, has also shown suggestive associa-
tion (Smith et al., 2011).
Several loci have shown association as part of the
OPPERA case-control study. DNA from chronic TMD
patients was screened using a SNP panel of 358 genes
implicated in pain through modulation of nociception,
psychological state or inﬂammatory response. Of the top
nine SNPs showing nominal statistically signiﬁcant
association, three are in the glucocorticoid receptor,
NR3C1; one in serotonin receptor 2A, HTR2A
(discussed above); one in muscarinic cholinergic
receptor 2, CHRM2; two in calcium/calmodulin-
dependent protein kinase 4, CAMK4; one in the
interferon-related developmental regulator 1, IFRD1;
and one in G protein-coupled receptor kinase 5, GRK5
(Smith et al., 2011). Another study, designed under the
hypothesis that TMD is a multifactorial syndrome related
to a critical period of human life with a genetic and epige-
netic basis, has investigated the possible involvement of
14 genes related to the folate cycle in TMD (Aneiros-
Guerrero et al., 2011). Three genes encoding enzymes
in the folate metabolizing pathway – serine hydrox-
ymethyltransferase 1, SHMT1; methylenetetrahydrofolate
dehydrogenase, MTHFD1; and methionine synthase
reductase, MTRR – have shown signiﬁcant associations
with TMD. Their risk alleles were associated with odds
ratios of having TMD that ranged from 2.35 to 3.99. In
addition, the authors have reported that a gene-deletion
polymorphism in GSTM1, encoding mu glutathione-S-
transferase (which is associated with inﬂammatory oxida-
tive stress), and the dopamine D4 receptor, DRD4, longallele of 48bp-repeat were associated with increased risk
of TMD.
A recent study has investigated the association of
SNPs occurring in ﬁve genes known to be important
regulators of the TGF-beta signaling pathway, which
plays a well-established role in the control of
chondrocyte diﬀerentiation, matrix synthesis and
homeostasis, and TMJ-OA. Of these, growth
diﬀerentiation factor 5, GDF5; SMAD family member 3,
SMAD3; and runt-related transcription factor 2, RUNX2
were associated with the pathogenesis of TMJ-OA (Xiao
et al., 2015). GDF5 is known to play a key role in bone
and cartilage morphogenesis as well as joint formation,
and the same genetic variant has been previously associ-
ated with knee osteoarthritis (OA) in Europeans and
Asians (Miyamoto et al., 2007; Chapman et al., 2008).
SMAD3 is a transcriptional modulator activated by TGF-
beta that is crucial to the integrity of articular cartilage,
and genetic variants in this gene have been implicated
in pathogenesis of knee OA in European and northeast-
ern Chinese populations (Valdes et al., 2010; Liying
et al., 2013). Lastly, RUNX2 is essential for osteoblast dif-
ferentiation and skeletal morphogenesis. Its contribution
to OA has been suggested in a large GWAS in Europeans
(arcOGEN Consortium, 2012).
In light of all the reported genetic associations, the
suggested pathophysiology of TMD pain is modulated
by pain regulators, inﬂammation-mediating cytokines,
and relevant tissue morphogenesis proteins.
Low back pain. Low back pain, whose heritability is
estimated to be up to 46% (Battie´ et al., 2007) is mainly
caused by disk disease (Sambrook et al., 1999) and char-
acterized by the desiccation of the spinal disk matrix (Guo
et al., 2011). Perhaps unsurprisingly, it has been associ-
ated with variants of genes encoding apoptosis-
mediating caspase, CASP9 (Guo et al., 2011; Mu et al.,
2013), and extracellular protein digestion enzyme, matrix
metalloproteinase, MMP1 (Song et al., 2008; Jacobsen
et al., 2013). Upstream of pathological proteoglycan
degradation is the overactive mixture of proinﬂammatory
cytokines, namely associated interleukins: interleukin
1A, IL1A (Solovieva et al., 2004; Omair et al., 2013;
Schistad et al., 2014) (which is also associated with treat-
ment response (Omair et al., 2013)); interleukin 1 recep-
tor antagonist, IL1RN (Solovieva et al., 2004; Loncˇar
et al., 2013); and interleukin 18 receptor subunits
encoded by IL18R1 and IL18RAP, both of which modulate
response to low back pain treatment (Omair et al., 2013).
Other associated genes include growth diﬀerentiation fac-
tor 5, GDF5, which participates in skeletal tissue diﬀeren-
tiation (Mu et al., 2013); beta-2 adrenergic receptor,
ADRB2, which is associated with low back pain comorbid
with neck pain (Skouen et al., 2012); catechol-O-
methyltransferase, COMT (Rut et al., 2014; Jacobsen
et al., 2012; Omair et al., 2012, 2015); estrogen receptor
1, ESR1 (Roh et al., 2013); guanosine triphosphate cyclo-
hydrolase, GCH1 (Tegeder et al., 2006); and mu opioid
receptor, OPRM1 (Hasvik et al., 2014) (although associa-
tion of this gene with low back pain has not been repli-
cated in Omair et al. (2015). The results of genetic
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disrupted tissue remodeling, with pain possibly resulting
from an overabundance of proinﬂammatory signaling.Fibromyalgia and CWP. Fibromyalgia is diagnosed
based on the presence of chronic widespread
musculoskeletal pain with tenderness in at least 11 of
18 sites on the body, fatigue, and sleep disturbance,
and it is frequently comorbid with mood disorders and
other chronic pain disorders (Mease, 2005; Lee et al.,
2012). Given its heritability of approximately 50%
(Markkula et al., 2009), genetic studies may provide valu-
able insight into the pathophysiology of ﬁbromyalgia.
Implicated genes show an over-representation of
monoaminergic pathway members: dopamine D4 recep-
tor, DRD4 (Buskila et al., 2004); catechol-O-
methyltransferase, COMT (Vargas-Alarco´n et al., 2007;
Ferna´ndez-de-las Pen˜as et al., 2012; Martı´nez-Jauand
et al., 2013; Barbosa et al., 2012; Cohen et al., 2009;
Finan et al., 2011; Matsuda et al., 2010); monoamine oxi-
dase, MAOA (Gu¨rsoy et al., 2008); beta-2 adrenergic
receptor, ADRB2 (Vargas-Alarco´n et al., 2009); serotonin
transporter, SLC6A4 (Oﬀenbaecher et al., 1999); sero-
tonin receptor 2A, HTR2A (Bondy et al., 1999; Gu¨rsoy
et al., 2001; Holliday et al., 2010; Mergener et al.,
2011); GTP cyclohydrolase, GCH1, an enzyme critical
to dopamine, serotonin, and nitric oxide production (Kim
et al., 2013); and trace amine associated receptor,
TAAR1 (Smith et al., 2012), a G protein-coupled receptor
with a regulatory role in dopaminergic neurotransmission
(Miller, 2011). Other associations include genes encoding
proteins more or less directly involved in neuronal inhibi-
tion and excitation, namely gamma-aminobutyric acid
(GABA) A receptor, GABRB3, Smith et al. (2012); sodium
channel NaV1.7, SCN9A (Vargas-Alarcon et al., 2012);
and two genes identiﬁed in a ﬁbromyalgia GWAS and
awaiting replication: myelin transcription factor 1-like,
MYT1L, which has a role in neuronal diﬀerentiation, and
neurexin, NRXN3, a synaptic scaﬀolding stabilizer
involved in glutamatergic and GABAergic neurotransmis-
sion (Docampo et al., 2014). Additionally, associations for
ﬁbromyalgia have been reported for apolipoprotein,
APOE (Reeser et al., 2011), and guanylate binding pro-
tein, GBP1 (Smith et al., 2012), a possible contributor to
inﬂammatory disease (de Buhr et al., 2006).
CWP, which substantially correlates with ﬁbromyalgia,
is deﬁned as pain present in the axial skeleton and in two
contralateral bodily quadrants for at least three months
(Gupta et al., 2007). A study targeting genes of the HPA
axis in CWP has found an association for glucosteroid
binding globulin, SERPINA6; corticotropin-releasing
hormone-binding protein, CRHBP; pro-opiomelanocortin,
POMC; and adrenocorticotropic hormone receptor,
MC2R (Holliday et al., 2010). A subsequent GWAS
meta-analysis conducted by the same group has found
a locus of susceptibility to CWP in a non-conding region
between the chaperonin-containing T-complex polypep-
tide 1 (TCP1)-complex-5 gene, CCT5, and FAMily with
sequence similarity 183 member B gene, FAM183B
(Peters et al., 2013). While the function of the latter pro-
tein is not known, CCT5 is a structural scaﬀolding subunitthat interacts with protein phosphatase PP4C and may be
involved in central sensitization (Peters et al., 2013).
Together, the genetic landscapes of ﬁbromyalgia and
CWP implicate a rewired nociceptive signaling system,
possibly disrupted by excessive stress response.
Stress-induced chronic pain. Recently, a number of
studies have shown an overlap of symptoms between
post-traumatic stress disorder and musculoskeletal pain
conditions (Cohen et al., 2002; Afari et al., 2008). Associ-
ations with glucocorticoid receptor co-chaperone, FKBP5
(Bortsov et al., 2013), and corticotropin releasing
hormone-binding protein, CRHBP (Linnstaedt et al.,
2016), two HPA axis-related genes, as well as mu opioid
receptor, OPRM1, and chronic musculoskeletal pain fol-
lowing a motor vehicle collision have been reported in a
cohort of 950 Caucasian Americans (Linnstaedt et al.,
2015) with replication in a sexual assault survivors’ cohort
for FKBP5 (Bortsov et al., 2013). The same study has
also shown that catechol-O-methyltransferase, COMT,
is associated with musculoskeletal pain several weeks fol-
lowing motor vehicle collision (McLean et al., 2011;
Bortsov et al., 2014). Ballina et al. have furthermore
reported a correlation between the same OPRM1 variant,
A118G, and muscle pain after sexual assault (Ballina
et al., 2013). They have also shown that widespread pain
after a motor vehicle collision is associated with pre-
accident depression, suggesting that pain was a factor
of the patient’s psychological characteristics (presumably
a proxy for genetic predisposition) rather than tissue injury
(Bortsov et al., 2013). In sum, these ﬁndings suggest that
genetic variability in the endogenous stress-management
and analgesia systems modulate susceptibility to muscu-
loskeletal pain conditions triggered by stress and psycho-
logical trauma.
Musculoskeletal condition genetics: summary. The
above overview of genes associated with
musculoskeletal chronic pain conditions highlights a
possible underlying pathophysiology. By the number of
reports, the contribution from the catecholaminergic
system, represented by COMT and ADRB2
associations, is seconded by the involvement of the
serotonergic system, exempliﬁed by associations with
HTR2A and SLC6A4 (Fig. 5). In terms of functional
pathways, neurotransmission is the most common
contributor (Fig. 6), followed by immune response
mediators. While neurotransmitters and inﬂammatory
cytokines are directly involved in pain signaling, the
other three functional groups may contribute to
musculoskeletal conditions by increasing susceptibility
to the underlying tissue damage.
Neuropathic pain disorders
Neuropathic pain disorders result from nerve dysfunction.
The eﬀect of genetic contributors diﬀers according to the
origin of this dysfunction. In rare monogenic disorders,
somatosensory function is maligned by causal mutations
in a single gene. The more common disorders with a
chronic neuropathic component are cancer, diabetes,
postoperative pain, and trigeminal neuralgia. For this
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modify an individual’s susceptibility to neuropathic pain
on the background of a diﬀerent underlying cause.Rare neuropathic pain disorders. Rare neuropathic
pain conditions fall into two categories: painless
disorders and painful disorders. Congenital insensitivity
to pain with anhidrosis, or inability to sense and respond
to noxious stimuli and to sweat, was the ﬁrst monogenic
neuropathic disorder to be reported. The causal
mutations were identiﬁed in the NTRK1 gene, which
encodes neurotrophic tyrosine kinase receptor (Indo
et al., 1996), an extensively replicated ﬁnding (Shatzky
et al., 2000; Miura et al., 2000; Bodzioch et al., 2001;
Indo, 2001; Indo et al., 2001; Bonkowsky et al., 2003;
Huehne et al., 2008; Li et al., 2012; Gao et al., 2013;
Liu et al., 2014; Yis et al., 2015; Tang et al., 2014;
Wang et al., 2015). A related disorder, congenital insensi-
tivity to pain, has been reported to be caused by loss-of-
function mutations in sodium channel Nav1.7-encoding
SCN9A (Cox et al., 2006, 2010; Kurban et al., 2010;
Klein et al., 2012; Peddareddygari et al., 2014; Mansouri
et al., 2014; Shorer et al., 2014). Interestingly, gain-of-
function mutations in another sodium channel, Nav1.9,
SCN11A, have also been implicated in this condition
(Leipold et al., 2013; Phatarakyijnirund et al., 2015).
Hyperactivity in Nav1.9 prolongs cell membrane depolar-
ization thereby inactivating Nav1.7 and Nav1.8 – the dri-
vers of the action potential in nociceptive neurons – and
blocking pain signal transmission.
Painful rare neuropathic pain disorders include
erythromelalgia, characterized by painful swelling and
severe redness in feet and hands, and paroxysmal
extreme pain disorder, characterized by rectal,
periocular and perimandibular pain. Causal SCN9A
mutations in erythromelalgia, discovered (Yang et al.,
2004) and replicated in a number of Chinese Asian fami-
lies (Li et al., 2005; Han et al., 2006; Zhang et al., 2006;
Lee et al., 2007; Lin et al., 2008) and Caucasian families
(Dib-Hajj et al., 2005; Drenth et al., 2005; Michiels et al.,
2005; Drenth et al., 2008; Samuels et al., 2008) have
been shown to change the electrophysiological properties
of dorsal root ganglion (DRG) neurons, believed to aﬀect
pain sensitivity (Cummins et al., 2004; Dib-Hajj et al.,
2005; Estacion et al., 2009). The eﬀects of paroxysmal
extreme pain disorder causal mutations (Fertleman
et al., 2006; Dib-Hajj et al., 2008; Estacion et al., 2008)
have been postulated to lie on a physiological continuum
with erythromelalgia. Estacion et al. have demonstrated
that alleles responsible for the former condition contribute
to impaired fast inactivation in pain-transmitting neurons,
while those responsible for the latter condition contribute
to a lower ﬁring threshold, slow deactivation and
enhanced ramp currents (Estacion et al., 2008).Cancer pain. Unlike the rare conditions discussed
above, in which chronic pain is caused by genetic
mutations of large eﬀect in one gene locus, genetic
variants contributing to cancer pain are found in several
loci and their eﬀect on pain is much more moderate.
The cause of cancer pain is usually a growing tumordirectly stimulating nociceptors, nerve damage during
chemotherapy (Costigan et al., 2009), and/or inﬂamma-
tory cytokines released by cancerous cells (Reyes-
Gibby et al., 2007). Interleukin-8, CXCL8 (Reyes-Gibby
et al., 2007); interleukin 1 receptor, IL1R1; and interleukin
13, IL13 (McCann et al., 2012), have been reported to be
associated with cancer pain severity. Reyes-Gibby et al.
have reported on the eﬀect of inﬂammation-related gene
polymorphisms on lung cancer pain severity, with associ-
ations for prostaglandin-endoperoxide synthase 2,
PTGS2; tumor necrosis factor, TNF; and NF-kappa B inhi-
bitor alpha, NFKBIA, with severe pain (Reyes-Gibby
et al., 2009). The additive eﬀect of variants in NOS3,
IL1B, TNFRSF1B, PTGS2, and IL10RB has been
reported to be implicated in the severe symptom cluster
in cancer patients, characterized by high pain intensity,
depression, and fatigue (Reyes-Gibby et al., 2013). As
with diabetes, while it may not be directly involved in the
pathophysiology of the underlying condition, hypersensi-
tivity of the body’s defense system appears to be con-
ducive to more pain accompanying cancer.Diabetic neuropathy. Diabetic neuropathy,
characterized by pain at one extreme and insensitivity at
the other is observed in up to 50% of diabetic patients
(Tesfaye and Selvarajah, 2012). Exacerbated by pro-
longed diabetic condition, glycemic mismanagement
(Tesfaye et al., 1996), and disruption of nerve microvas-
culature (Tesfaye and Selvarajah, 2012) this neuropathy
presents as a multifactorial pathology that is likely to be
substantially driven by genetic factors. Unfortunately, dia-
betic pain genetic association studies are scarce, and
existing results have to date painted a far-from-complete
picture of its pathophysiology. Nevertheless, it is notewor-
thy that a hypofunctional polymorphism in mu opioid
receptor,OPRM1, is associated with foot ulcer pain in dia-
betic patients (Cheng et al., 2010), while hyperfunctional
variants in purinergic receptor 7, P2RX7, are reported to
be associated with higher pain sensitivity in diabetic neu-
ropathic women (Ursu et al., 2014). Insuﬃcient endoge-
nous pain regulation (OPRM1) and excess high alert
signaling (P2RX7) appear to contribute to baseline noci-
ceptive hypersensitivity, which exacerbates diabetes-
related pain.Postoperative pain. Postoperative pain is usually
considered persistent, or chronic, when it is reported at
least three months after surgery. The complementary
nociceptive and inhibitory systems are implicated in
several examples from postoperative pain studies: Kim
et al. have reported an association between a variant in
GTP hydrolase, GCH1, and postoperative pain (Kim
et al., 2010); Tegeder et al. have identiﬁed an association
between postoperative pain and a haplotype of the same
gene (Tegeder et al., 2006) (not replicated either at the
SNP or haplotype level in Hendry et al. (2013)); and two
groups have reported that mu opioid receptor, OPRM1,
genotypes predict the extent of chronic postoperative pain
(Kolesnikov et al., 2013; Olsen et al., 2012). The latter
group has shown that the eﬀect of the OPRM1 variant is
sex-speciﬁc, such that allele G118 confers risk of pain in
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variant in voltage-gated potassium channel subunit,
KCNS1, has been reported as correlated with postopera-
tive chronic pain intensity in two limb amputation cohorts
and one post-mastectomy cohort (Costigan et al., 2010).
Another post-mastectomy cohort study (Sorge et al.,
2012) has reported an association for a purinergic recep-
tor 7, P2RX7, variant. Additionally, a COMT polymor-
phism has been reported to be associated with pain one
year after lumbar discectomy (Rut et al., 2014).
Genetic variants of inﬂammatory cytokines have also
been demonstrated to play a role in the risk of
neuropathic pain following surgery. Stephens et al. have
reported an association between a SNP of interleukin 1
receptor, IL1R2, and a haplotype within interleukin 10,
IL10, with persistent breast pain after surgery for breast
cancer (Stephens et al., 2014).Trigeminal neuralgia. Trigeminal neuralgia is the most
common type of neuralgia in adults with an estimated
annual incidence of 4–13 per 100,000 people (Katusic
et al., 1991; MacDonald et al., 2000). Trigeminal neuralgia
is characterized by sudden, usually unilateral, severe,
brief, stabbing recurrent episodes of pain within the distri-
bution of one or more branches of the trigeminal nerve,
triggered by innocuous stimuli (Kraﬀt, 2008). To date,
the precise mechanisms of trigeminal neuralgia remain
unclear, and only a few studies have been conducted
on the genetics of this condition.
The role of the serotonin transporter, SLC6A4, 44bp
insertion/deletion polymorphism in susceptibility to
trigeminal neuralgia and its clinical features, especially
the pain severity and treatment response to analgesics,
has been recently investigated (Cui et al., 2014). The s
variant carriers had a signiﬁcantly higher risk of trigeminal
neuralgia pain severity and of carbamazepine treatment
failure. These ﬁndings are contrary to those reported for
TMD (Ojima et al., 2007); however, chronic pain condi-
tions of musculoskeletal and neuropathic origins have
substantially diﬀerent components, and this apparent con-
tradiction is not surprising.Other painful peripheral neuropathic conditions. Sev-
eral other peripheral neuropathic pain conditions have
been reported. Haplotypes in voltage-gated potassium
channel subunit, KCNS1, have shown association with
pain intensity in HIV-associated sensory neuropathy
among black South Africans (Hendry et al., 2013). Chan-
nels, TRPA1 and TRPV1, have been reported to aﬀect
somatosensory sensitivity in neuropathic pain patients
who suﬀered from a variety of neuropathic conditions
(Binder et al., 2012). SCN9A has likewise been reported
to be associated with unexplained chronic neuropathic
pain (Dabby et al., 2011).
Three sodium channels have also been reported to be
associated with a more common neuropathic pain
condition, painful small-ﬁber neuropathy. Aﬀecting small-
diameter A-delta and C ﬁbers and characterized by
sudden bouts of pain originating in the extremities, this
condition has been reported to be associated with
Nav1.7, SCN9A (Faber et al., 2012a; Han et al., 2012);Nav1.8, SCN10A (Faber et al., 2012b; Huang et al.,
2013; Dabby et al., 2016); and Nav1.9, SCN11A (Huang
et al., 2014; Han et al., 2015). The relevant mutations in
these channels have been functionally characterized
and found to contribute to sensory neuron hyperexcitabil-
ity (Faber et al., 2012a,b; Han et al., 2012, 2015; Huang
et al., 2013, 2014).
Neuropathic condition genetics: summary. Unlike in
migraine and musculoskeletal pain conditions, our
understanding of genetic contributors to neuropathic
pain is largely derived from rare familial mutations and
is dominated by sodium channels. While Nav1.7, and to
a lesser extent Nav1.8 and Nav1.9, have been
repeatedly reported as causal in rare neuropathic pain
conditions, the direction and extent of functional eﬀect
on the disease phenotype is tied to the speciﬁc mutation
or mutations within each locus. Moreover, extensive
pedigree segregation analysis and electrophysiological
characterization have occasionally shown previously
reported causal mutations as benign or conferring a mild
risk (Klein et al., 2012; Waxman et al., 2014).
Genetic variants underlying common neuropathic pain
conditions also point to modulation of neurotransmission
and related pathways. Three of the four genes whose
association has been replicated at least once – GCH1,
a regulator in the dopamine, serotonin, and nitric oxide
biosynthesis pathway; KCNS1, a voltage-gated
potassium channel subunit; and OPRM1, one of the
body’s endogenous pain regulators – implicate
dysregulation in pain processing. The other gene, twice
reported to be associated with cancer pain, is PTGS2,
which indicates involvement of the immune system.
Visceral pain disorders
Visceral pain disorders, reviewed in Dabby et al. (2011)
and Cervero and Laird (1999), are characterized by pain
stemming from visceral organs. At least in part due to lack
of consensus on diagnostic criteria for these conditions,
genetic studies have been few and have provided but a
glimpse into their pathophysiology, with tenuous connec-
tions between implicated genes. Possible involvement of
genetic polymorphisms has been reported for chronic pel-
vic pain, chronic pancreatitis and interstitial cystitis.
Chronic pelvic pain is a pathology believed to result
from certain bacterial infections and sexually-transmitted
disease sequelae (Pontari, 2013). Evidence for inﬂamma-
tory dysregulation comes from a study showing that
chronic pelvic pain patients were more likely to express
the genotype associated with reduced production of the
regulatory cytokine interleukin 10, IL10 (Shoskes et al.,
2002). An early study by Riley et al. has implicated a short
tandem repeat region of the X chromosome near the
phosphoglycerate kinase gene, PGK1, in chronic prostati-
tis/chronic pelvic pain (Riley and Krieger, 2002). Two
other genes possibly implicated in chronic pelvic pain
are manganese superoxide dismutase, MNSOD (Arisan
et al., 2006), and androgen receptor, AR (Pontari, 2013).
Several genes have been reported to be associated
with chronic pancreatitis with pain. Variants of cystic
ﬁbrosis transmembrane conductance regulator, CFTR
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(a chloride channel whose more damaging mutations lead
to cystic ﬁbrosis); serine protease inhibitor, SPINK1 (Witt
et al., 2000; Pfuetzer et al., 2001), which regulates
trypsinogen; cationic trypsinogen, PRSS1 (Gorry et al.,
1997), which in its hyperactive form essentially autodi-
gests the pancreas; and trypsin inhibitor, PSTI (Noone
et al., 2001), have all been reported to be associated with
chronic pancreatitis with pain. PRSS1 also carries muta-
tions that cause hereditary pancreatitis (Whitcomb et al.,
1996; Noone et al., 2001; Simon et al., 2002; Le
Marechal et al., 2004; Le Mare´chal et al., 2006), as does
SPINK1 (Kira´ly et al., 2007).
Interstitial cystitis, characterized by bladder pain, has
been found associated with a potentiating variant of
sodium channel NaV1.7, SCN9A (Reeder et al., 2013).
Visceral condition genetics: summary. Genetic studies
of visceral conditions have thus far not painted a clear
picture of the biological pathways involved in their
pathophysiology. SCN9A, whose involvement in visceral
chronic pain has been reported four times, appears to
be the most frequent contributor to chronic pain
accompanying visceral disorders. Given this gene’s
well-established role in a number of rare monogenic
pain conditions, its possible role in visceral pain may be
yet another manifestation of disrupted pain signaling.
Furthermore, the four genes whose associations with
visceral disorders have been replicated at least once
represent three diﬀerent functional pathways: SCN9A –
neurotransmission, PRSS1 and SPINK1 – protein
degradation, and CFTR – immune response. This
evidence from genetic studies to date suggests that
visceral pain disorders may not have a common
pathophysiology and are rather grouped together
primarily based on the anatomical proximity of the
aﬀected organs.
CONCLUSION
Genetic studies conducted in the last two decades have
been invaluable in elucidating the molecular
pathophysiology mechanisms of chronic pain conditions.
While these studies have occasionally suﬀered from
contradictory results or insuﬃcient statistical power to
conﬁrm the involvement of speciﬁc genes, the network
of causal mechanisms is nevertheless gradually coming
into focus. Genetic variants contributing to chronic pain
conditions characterize these conditions as multifactorial
pathologies with overlapping etiologies. All chronic pain
condition categories show an enrichment for genes
involved in neurotransmission, underscoring the
importance of neuronal signaling – speciﬁcally
ascending nociceptive and descending inhibitory
signaling – in pain chronicity. Nevertheless, secondary
functional pathways diﬀer between the etiologically
grouped categories and shed light on possible
pathophysiological diﬀerences between them. This
suggests that distinct combinations of genetic variants,
presumably interacting with environmental factors,
determine the speciﬁc pathology that develops. Thus
identiﬁcation of genetic contributors of chronic painconditions builds our understanding not only of the
genotypic structure of these diseases but also of their
molecular pathophysiology.
Furthermore, currently available chronic pain
treatments are fraught with signiﬁcant obstacles,
including unmanageable side eﬀects (Furlan et al.,
2006; Chou et al., 2015) and variable eﬀectiveness at
the population level (Turk, 2002; Ballantyne and Shin,
2008; Finnerup et al., 2010), which are attributable to
interindividual variability in pharmacokinetic and pharma-
codynamic properties of analgesics. Perhaps even more
importantly, given that chronic pain conditions are a
heterogeneous class of disorders, driven by diﬀerent
pathways of vulnerability that include diﬀerential molecu-
lar genetic contribution, genetic studies promise to identify
key molecular markers of susceptibility and targets for
personalized treatment of chronic pain. Therefore the
results of genetic studies should be exploited for drug
development targeting of molecular pathways unique –
or as close to unique as possible – to each pathology.Acknowledgments—The authors would like to thank Dr. Ryan
Nicholas Lichtenwalter for his careful reading of the manuscript
and helpful comments as well as for his invaluable assistance
with LaTeX formatting.REFERENCES
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